Sunday 18 October 2026
Export VNDA’s income statement to Excel — free account
Vanda Pharmaceuticals Inc.
VNDA Healthcare Biotechnology
Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.
4.03
0.21
−4.95%
Follow VNDA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 52.26 | 7.56 | 30.56 | 26.15 | 61.83 | 86.26 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 5 | 7 | 4 | 6 | 6 | 4 | 5 | 3 | 2 |
Altman Z-Score |
4.07 | 4.16 | 14.34 | 7.90 | 6.24 | 7.00 | 3.23 | 1.93 | 1.77 | 0.72 |
P/S ratio |
4.64 | 4.23 | 6.89 | 3.84 | 2.88 | 3.24 | 1.65 | 1.35 | 1.40 | 2.41 |
P/FCF ratio |
0.00 | 0.00 | 288.01 | 43.76 | 28.63 | 22.54 | 66.45 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.35) | (1.25) | 7.10 | 8.75 | 9.29 | 10.00 | 8.85 | 8.09 | 6.91 | 0.13 |
Beneish M-Score |
(2.57) | (2.95) | (1.83) | (1.02) | (2.79) | (2.71) | (2.72) | (2.09) | (2.27) | (3.88) |
P/Operating CF |
(572.96) | 201.35 | 87.14 | 89.06 | 37.05 | 32.76 | 44.49 | (69.50) | (153.29) | (17.67) |
P/B ratio |
5.16 | 5.31 | 4.83 | 2.12 | 1.58 | 1.73 | 0.79 | 0.48 | 0.52 | 1.59 |
Price to Tangible BV |
6.55 | 6.63 | 5.30 | 2.25 | 1.66 | 1.80 | 0.82 | 0.61 | 0.66 | 2.47 |
EV/Sales |
3.67 | 3.36 | 5.55 | 2.52 | 1.45 | 1.67 | (0.15) | (0.63) | (0.47) | 1.20 |
EV/EBITDA |
0.00 | 0.00 | 47.73 | 25.32 | 11.85 | 9.62 | 0.00 | 6.59 | 2.46 | 0.00 |
EV/Operating CF |
(66.21) | (279.60) | 35.77 | 12.46 | 6.93 | 6.99 | (1.22) | (9.49) | 5.90 | (2.38) |
EV/FCF |
(29.44) | (152.03) | 232.28 | 28.72 | 14.37 | 11.61 | (6.20) | 1.07 | 2.04 | (2.35) |
Quick Ratio |
3.21 | 2.29 | 5.40 | 5.69 | 6.03 | 6.25 | 5.47 | 4.82 | 4.22 | 2.19 |
Current Ratio |
3.46 | 2.41 | 5.64 | 5.95 | 6.21 | 6.43 | 5.68 | 4.94 | 4.39 | 2.39 |
Net Debt/EBITDA |
21.09 | 10.00 | (11.45) | (13.26) | (11.76) | (9.06) | (75.10) | 21.08 | 9.81 | 1.84 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 2.57% | 2.16% | 1.69% | 1.39% | 0.00% | 0.48% | 0.83% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.01 | 0.01 |
Asset Turnover |
0.69 | 0.79 | 0.72 | 0.56 | 0.49 | 0.48 | 0.41 | 0.30 | 0.30 | 0.38 |
Operating CF/Net income |
0.45 | 0.13 | 1.19 | 0.40 | 2.22 | 1.94 | 5.10 | 5.10 | 0.83 | 0.50 |
Capex/Depreciation |
(0.12) | (0.65) | (34.51) | 4.92 | (0.59) | (0.12) | 2.95 | 22.63 | (1.68) | (0.10) |
| (13.63%) | (11.85%) | 12.39% | 33.67% | 5.40% | 6.92% | 1.22% | 0.47% | (3.49%) | (50.93%) | |
| (8.51%) | (7.49%) | 9.38% | 28.33% | 4.59% | 5.88% | 1.02% | 0.39% | (2.90%) | (38.51%) | |
ROIC |
0.00% | 0.00% | 75.22% | 12.81% | 17.55% | 32.07% | 5.72% | (5.57%) | (15.21%) | (140.15%) |
Return on Tangible Assets |
(13.98%) | (14.85%) | 10.06% | 38.71% | 6.72% | 8.15% | 1.46% | 0.72% | (5.54%) | (107.89%) |
Average Days of Receivables |
50.66 | 38.92 | 54.40 | 42.36 | 44.18 | 44.11 | 48.08 | 64.71 | 86.49 | 92.18 |
Research and Development Expense of Revenue |
19.97% | 23.35% | 22.57% | 21.41% | 22.39% | 28.05% | 33.72% | 39.88% | 37.45% | 50.56% |
Selling, General and Administrative Expense of Revenue |
68.34% | 75.02% | 54.76% | 57.11% | 56.62% | 46.17% | 53.65% | 58.60% | 73.66% | 110.11% |
Intangible Assets out of Total Assets |
0.13 | 0.13 | 0.07 | 0.05 | 0.04 | 0.03 | 0.03 | 0.19 | 0.17 | 0.24 |
Share Based Compensation of Revenue |
5.85% | 6.34% | 6.04% | 5.92% | 5.38% | 5.72% | 6.40% | 7.29% | 6.25% | 4.38% |
Graham Net Nets |
0.14 | 0.14 | 0.18 | 0.32 | 0.46 | 0.45 | 0.98 | 1.27 | 1.15 | 0.36 |
Graham Number |
0.00 | 0.00 | 7.80 | 19.43 | 8.98 | 11.08 | 5.02 | 3.35 | 0.00 | 0.00 |
Earnings Yield |
(2.70%) | (2.18%) | 1.91% | 13.22% | 3.27% | 3.82% | 1.62% | 1.16% | (6.68%) | (42.29%) |
Free Cash Flow Yield |
(2.69%) | (0.52%) | 0.35% | 2.29% | 3.49% | 4.44% | 1.50% | (43.66%) | (16.33%) | (21.25%) |
Revenue per Share |
3.36 | 3.69 | 3.79 | 4.28 | 4.56 | 4.84 | 4.51 | 3.36 | 3.42 | 3.67 |
Operating CF per Share |
(0.19) | (0.04) | 0.59 | 0.86 | 0.95 | 1.16 | 0.57 | 0.22 | (0.27) | (1.86) |
Capex per Share |
(0.03) | (0.04) | (0.50) | (0.02) | (0.03) | (0.01) | (0.01) | (1.76) | (0.08) | (0.02) |
Free Cash Flow per Share |
(0.22) | (0.08) | 0.09 | 0.85 | 0.92 | 1.15 | 0.55 | (1.54) | (0.35) | (1.87) |
Cash per Share |
3.25 | 3.21 | 5.06 | 5.87 | 6.76 | 7.79 | 8.27 | 6.77 | 6.44 | 4.48 |
Shareholders Equity per Share |
3.02 | 2.94 | 5.41 | 7.73 | 8.33 | 9.09 | 9.34 | 9.50 | 9.26 | 5.55 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.02 | 2.94 | 5.41 | 7.73 | 8.33 | 9.09 | 9.34 | 9.50 | 9.26 | 5.55 |
Free Cash Flow |
(9.51) | (3.65) | 4.62 | 44.93 | 49.98 | 63.66 | 31.31 | (88.25) | (20.48) | (110.44) |
Working Capital |
123.86 | 99.49 | 246.12 | 294.63 | 343.21 | 403.88 | 427.86 | 345.25 | 338.91 | 202.10 |
Capital Expenditures |
(1.41) | (1.66) | (25.37) | (1.02) | (1.79) | (0.55) | (0.68) | (101.05) | (4.72) | (1.00) |
Net Current Asset Value |
95.13 | 95.82 | 242.42 | 281.33 | 328.96 | 389.44 | 412.24 | 329.42 | 321.23 | 185.50 |
EV/EBIT |
0.00 | 0.00 | 49.34 | 25.09 | 13.18 | 10.64 | 0.00 | 8.70 | 2.29 | 0.00 |
Capex to Sales |
0.01 | 0.01 | 0.13 | 0.00 | 0.01 | 0.00 | 0.00 | 0.52 | 0.02 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 61.18 | 38.23 | 26.26 | 20.67 | 66.20 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.37 | 0.48 | 0.17 | (0.05) | 0.74 | 1.44 | (0.09) | (2.19) | 1.32 | 4.39 |
Cash ROIC |
(3.49%) | (1.33%) | 0.87% | 6.11% | 6.00% | 6.72% | 3.12% | (9.46%) | (2.23%) | (18.56%) |
Accounts Receivable Turnover |
7.98 | 8.72 | 8.33 | 8.24 | 8.80 | 8.60 | 7.71 | 5.69 | 4.89 | 4.25 |
Accounts Payable Turnover |
1.55 | 0.98 | 0.98 | 1.00 | 0.79 | 0.78 | 0.61 | 0.35 | 0.29 | 0.24 |
Inventory Turnover |
23.84 | 22.05 | 22.36 | 22.95 | 19.31 | 22.24 | 21.89 | 11.60 | 7.34 | 7.29 |
Average Days of Payables |
239.22 | 415.86 | 384.15 | 411.24 | 492.24 | 490.46 | 684.71 | 948.76 | 1,260.95 | 1,911.10 |
Days of Inventory on Hand |
11.51 | 17.18 | 17.69 | 16.99 | 20.00 | 14.60 | 17.95 | 33.48 | 55.68 | 51.82 |
Average Receivables |
18.30 | 18.93 | 23.19 | 27.57 | 28.20 | 31.25 | 32.99 | 33.83 | 40.63 | 50.84 |
Average Payables |
15.98 | 18.27 | 20.96 | 24.59 | 29.55 | 32.97 | 39.99 | 42.01 | 38.77 | 53.69 |
Average Inventory |
1.04 | 0.81 | 0.92 | 1.07 | 1.21 | 1.15 | 1.11 | 1.28 | 1.54 | 1.79 |
Average Assets |
211.71 | 207.90 | 268.78 | 407.94 | 508.60 | 563.62 | 614.02 | 641.34 | 652.32 | 572.58 |
Average Common Equity |
132.18 | 131.36 | 203.40 | 343.18 | 432.11 | 479.10 | 516.06 | 536.05 | 541.73 | 432.87 |
Columns are period end dates